Recent research have centered on the intersection of glucagon-like peptide-1|GIP|glucagon receptor activator therapies and dopamine signaling. While GIP agonists are increasingly employed for addressing type 2 T2DM, their emerging effects on motivation circuits, specifically governed by dopamine networks, are receiving significant focus. This pa… Read More